The proportion of patients who met the criterion for PASI @ at week @ was higher with each secukinumab dose than with placebo or etanercept : in the ERASURE study , the rates were @ % with @ mg of secukinumab , @ % with @ mg of secukinumab , and @ % with placebo ; in the FIXTURE study , the rates were @ % with @ mg of secukinumab , @ % with @ mg of secukinumab , @ % with etanercept , and @ % with placebo ( P < @ for each secukinumab dose vs. comparators ) .